Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematological disorders, cancer and rare immune diseases.

Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference

View Press Release View All

Aug 2, 2022 • 4:02pm EDT

Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022 • 4:01pm EDT

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Jul 26, 2022 • 8:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update

August 2022

View Presentation

H.C. Wainwright 24th Annual Global Investment Conference

View Event View All

Q2 2022

Quarter Ended Jun 30, 2022

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080